Back to All Combinations

PIK3CA Exon 20

Intermediate Prognosis
7.00% Prevalence Level 2A PIK3CA Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
PIK3CA
Treatment Implications

Strong aspirin benefit data. Regular aspirin improves survival.

Recommended Treatments
Standard chemotherapy
Aspirin
PI3K inhibitor trials
Treatments to Avoid

No specific contraindications noted

Study References

Liao et al NEJM 2012

Key Statistics
7.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Discuss aspirin with patient if no contraindications.
Information

Category: PIK3CA Pathway

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.